Patheon said today it has agreed to acquire an active pharmaceutical ingredients (API) manufacturing facility in Florence, SC, from Roche for an undisclosed price.
The 1100-acre, 300,000-square-foot facility includes manufacturing capacity for API ranging from development to manufacturing services, Patheon said.
With the addition of the Florence site, Patheon added, it will expand its capacity for manufacturing highly potent compounds and add capabilities to support solid-state chemistry, micronization, and eventually commercial spray drying.
“The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals,” Patheon CEO James Mullen said in a statement.
Patheon has approximately 8000 employees worldwide.
Patheon said the Florence site will provide it with a major U.S. API operation capable of supporting products from clinical scale to commercial manufacturing and further enhance the company’s scientific and technical expertise.
The site features reactors ranging from 50 to 11,000 liters producing multiple products simultaneously, fully compliant with all applicable regulations, such as cGMP safety and environmental standards.
Patheon’s acquisition includes the site as well as the cost of associated inventory and spare parts. The company also entered into a multiyear supply agreement with Roche that, according to Patheon, is expected to help defray the costs associated with running the site for the next “few” years while it brings to the facility work generated by its own clients.